LYN-005’s once-weekly dosing regimen reduces the pill burden for individuals with schizophrenia and schizoaffective disorders compared to traditional daily medications such as Risperdal.
A unique capsule design consisting of six polymeric arms connected to a flexible core, encapsulated in a folded star-shaped formulation allows for sustained release of LYN-005 over the week, ensuring consistent therapeutic levels in the body.
Lyndra Therapeutics, a company dedicated to pioneering innovative treatments for Schizophrenia, delivered a compelling presentation at the Congress of the Schizophrenia International Research Society (SIRS) in Florence, Italy, spanning fr...